

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II

SAFETY DATA SHEET

AMCA-Affinity-Purified Antibodies and -Streptavidin, freeze-dried with preservative

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name: AMCA -Conjugated Antibodies and -Streptavidin , freeze-dried with preservative

Product code:

016-150-084	109-156-003	112-155-072	115-156-068	305-155-006	312-155-045	515-155-062	715-156-020
101-155-003	109-156-006	112-155-075	115-156-071	305-155-008	312-155-046	515-155-071	715-156-150
101-155-165	109-156-008	112-155-143	115-156-072	305-155-045	312-155-047	515-155-072	715-156-151
101-156-003	109-156-011	112-155-167	115-156-075	305-155-046	312-155-048	703-155-155	805-155-180
102-155-003	109-156-064	112-156-003	123-155-021	305-155-047	312-155-049	703-156-155	-
102-155-006	109-156-088	112-156-062	127-155-099	305-156-003	312-156-045	705-155-003	-
102-155-008	109-156-097	112-156-068	127-155-160	305-156-006	313-155-003	705-155-147	-
103-155-155	109-156-098	112-156-071	200-152-037	305-156-008	313-155-045	705-156-147	-
106-155-003	109-156-127	112-156-072	200-152-156	305-156-045	313-155-046	706-155-148	-
106-155-006	109-156-129	112-156-075	200-152-211	305-156-046	313-155-047	706-156-148	-
106-155-008	111-155-003	114-155-003	205-155-108	305-156-047	313-156-003	709-155-073	-
106-156-003	111-155-006	115-155-003	209-155-082	307-155-003	315-155-003	709-155-098	-
107-155-142	111-155-008	115-155-006	209-155-088	307-156-003	315-155-006	709-155-149	-
107-156-142	111-155-045	115-155-008	209-155-097	308-155-003	315-155-008	709-156-073	-
108-155-003	111-155-046	115-155-020	209-155-098	309-155-003	315-155-020	709-156-098	-
108-155-008	111-155-047	115-155-044	211-155-109	309-155-006	315-155-044	709-156-149	-
108-156-003	111-155-144	115-155-062	212-155-082	309-155-008	315-155-045	711-155-152	-
109-155-003	111-156-003	115-155-068	212-155-104	309-155-011	315-155-046	711-156-152	-
109-155-006	111-156-045	115-155-071	212-155-106	309-155-015	315-155-047	712-155-150	-
109-155-008	111-156-046	115-155-072	212-155-168	309-155-064	315-155-048	712-155-153	-
109-155-011	111-156-047	115-155-075	212-156-168	309-155-082	315-155-049	712-156-150	-
109-155-043	112-155-003	115-155-146	301-155-003	309-155-095	315-156-003	712-156-153	-
109-155-044	112-155-006	115-155-164	303-155-003	309-155-107	315-156-045	713-155-003	-
109-155-064	112-155-008	115-155-166	303-155-006	309-156-003	315-156-046	713-155-147	-
109-155-088	112-155-020	115-156-003	303-155-008	309-156-008	315-156-047	713-156-147	-
109-155-097	112-155-044	115-156-006	303-156-003	309-156-043	323-155-021	715-155-020	-
109-155-098	112-155-062	115-156-008	304-155-003	312-155-003	415-155-166	715-155-140	-
109-155-127	112-155-068	115-156-020	304-155-008	312-155-020	415-156-166	715-155-150	-
109-155-129	112-155-071	115-156-062	305-155-003	312-155-044	515-155-003	715-155-151	-

SDS #: 32EU

Product description:

016-150-084	AMCA-Streptavidin
101-155-003	AMCA-AffiniPure Goat Anti-Bovine IgG (H+L)
101-155-165	AMCA-AffiniPure Goat Anti-Bovine IgG (H+L) (min X Ar Hms,Hu,Ms,Rat Sr Prot)
101-156-003	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Bovine IgG (H+L)
102-155-003	AMCA-AffiniPure Goat Anti-Cat IgG (H+L)
102-155-006	AMCA-AffiniPure Goat Anti-Cat IgG, F(ab)2 Fragment Specific
102-155-008	AMCA-AffiniPure Goat Anti-Cat IgG, Fc Fragment Specific
103-155-155	AMCA-AffiniPure Goat Anti-Chicken IgY (IgG) (H+L) (min X Bov,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
106-155-003	AMCA-AffiniPure Goat Anti-Guinea Pig IgG (H+L)
106-155-006	AMCA-AffiniPure Goat Anti-Guinea Pig IgG, F(ab)2 Fragment Specific
106-155-008	AMCA-AffiniPure Goat Anti-Guinea Pig IgG, Fc Fragment Specific
106-156-003	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Guinea Pig IgG (H+L)
107-155-142	AMCA-AffiniPure Goat Anti-Syrian Hamster IgG (H+L) (min X Bov,Hrs,Hu,Ms,Rb,Rat Sr Prot)
107-156-142	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Syrian Hamster IgG (H+L) (min X Bov,Hrs,Hu,Ms,Rb,Rat Sr Prot)
108-155-003	AMCA-AffiniPure Goat Anti-Horse IgG (H+L)
108-155-008	AMCA-AffiniPure Goat Anti-Horse IgG, Fc Fragment Specific
108-156-003	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Horse IgG (H+L)
109-155-003	AMCA-AffiniPure Goat Anti-Human IgG (H+L)
109-155-006	AMCA-AffiniPure Goat Anti-Human IgG, F(ab)2 Fragment Specific
109-155-008	AMCA-AffiniPure Goat Anti-Human IgG, Fcy Fragment Specific
109-155-011	AMCA-AffiniPure Goat Anti-Human Serum IgA, α Chain Specific
109-155-043	AMCA-AffiniPure Goat Anti-Human IgM, Fc5μ Fragment Specific
109-155-044	AMCA-AffiniPure Goat Anti-Human IgG + IgM (H+L)
109-155-064	AMCA-AffiniPure Goat Anti-Human IgA + IgG + IgM (H+L)
109-155-088	AMCA-AffiniPure Goat Anti-Human IgG (H+L) (min X Bov,Hrs,Ms Sr Prot)
109-155-097	AMCA-AffiniPure Goat Anti-Human IgG, F(ab)2 Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
109-155-098	AMCA-AffiniPure Goat Anti-Human IgG, Fcy Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
109-155-127	AMCA-AffiniPure Goat Anti-Human IgG + IgM (H+L) (min X Bov Sr Prot)
109-155-129	AMCA-AffiniPure Goat Anti-Human IgM, Fc5μ Fragment Specific (min X Bov Sr Prot)
109-156-003	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgG (H+L)
109-156-006	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgG, F(ab)2 Fragment Specific
109-156-008	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgG, Fcy Fragment Specific
109-156-011	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human Serum IgA, α Chain Specific
109-156-064	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgA + IgG + IgM (H+L)
109-156-088	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgG (H+L) (min X Bov,Hrs,Ms Sr Prot)
109-156-097	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgG, F(ab)2 Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
109-156-098	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgG, Fcy Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
109-156-127	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgG + IgM (H+L) (min X Bov Sr Prot)
109-156-129	AMCA-AffiniPure F(ab)2 Fragment Goat Anti-Human IgM, Fc5μ Fragment Specific (min X Bov Sr Prot)

111-155-003 AMCA-AffiniPure Goat Anti-Rabbit IgG (H+L)
111-155-006 AMCA-AffiniPure Goat Anti-Rabbit IgG, F(ab')₂ Fragment Specific
111-155-008 AMCA-AffiniPure Goat Anti-Rabbit IgG, Fc Fragment Specific
111-155-045 AMCA-AffiniPure Goat Anti-Rabbit IgG (H+L) (min X Hu Sr Prot)
111-155-046 AMCA-AffiniPure Goat Anti-Rabbit IgG, Fc Fragment Specific (min X Hu Sr Prot)
111-155-047 AMCA-AffiniPure Goat Anti-Rabbit IgG, F(ab')₂ Fragment Specific (min X Hu Sr Prot)
111-155-144 AMCA-AffiniPure Goat Anti-Rabbit IgG (H+L) (min X Hu,Ms,Rat Sr Prot)
111-156-003 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rabbit IgG (H+L)
111-156-045 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rabbit IgG (H+L) (min X Hu Sr Prot)
111-156-046 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rabbit IgG, Fc Fragment Specific (min X Hu Sr Prot)
111-156-047 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rabbit IgG, F(ab')₂ Fragment Specific (min X Hu Sr Prot)
112-155-003 AMCA-AffiniPure Goat Anti-Rat IgG (H+L)
112-155-006 AMCA-AffiniPure Goat Anti-Rat IgG, F(ab')₂ Fragment Specific
112-155-008 AMCA-AffiniPure Goat Anti-Rat IgG, Fcy Fragment Specific
112-155-020 AMCA-AffiniPure Goat Anti-Rat IgM, μ Chain Specific
112-155-044 AMCA-AffiniPure Goat Anti-Rat IgG + IgM (H+L)
112-155-062 AMCA-AffiniPure Goat Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
112-155-068 AMCA-AffiniPure Goat Anti-Rat IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)
112-155-071 AMCA-AffiniPure Goat Anti-Rat IgG, Fcy Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
112-155-072 AMCA-AffiniPure Goat Anti-Rat IgG, F(ab')₂ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
112-155-075 AMCA-AffiniPure Goat Anti-Rat IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)
112-155-143 AMCA-AffiniPure Goat Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Rb Sr Prot)
112-155-167 AMCA-AffiniPure Goat Anti-Rat IgG (H+L) (min X Ms, Hu,Bov,Hrs,Rb Sr Prot)
112-156-003 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rat IgG (H+L)
112-156-062 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
112-156-068 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rat IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)
112-156-071 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rat IgG, Fcy Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
112-156-072 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rat IgG, F(ab')₂ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
112-156-075 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Rat IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)
114-155-003 AMCA-AffiniPure Goat Anti-Swine IgG (H+L)
115-155-003 AMCA-AffiniPure Goat Anti-Mouse IgG (H+L)
115-155-006 AMCA-AffiniPure Goat Anti-Mouse IgG, F(ab')₂ Fragment Specific
115-155-008 AMCA-AffiniPure Goat Anti-Mouse IgG, Fcy Fragment Specific
115-155-020 AMCA-AffiniPure Goat Anti-Mouse IgM, μ Chain Specific
115-155-044 AMCA-AffiniPure Goat Anti-Mouse IgG + IgM (H+L)
115-155-062 AMCA-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-155-068 AMCA-AffiniPure Goat Anti-Mouse IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-155-071 AMCA-AffiniPure Goat Anti-Mouse IgG, Fcy Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-155-072 AMCA-AffiniPure Goat Anti-Mouse IgG, F(ab')₂ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-155-075 AMCA-AffiniPure Goat Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)
115-155-146 AMCA-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs,Rb,Sw Sr Prot)
115-155-164 AMCA-AffiniPure Goat Anti-Mouse IgG (subclasses 1+2a+2b+3), Fcy Fragment Specific (min X Hu,Bov,Rb Sr Prot)
115-155-166 AMCA-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Rat,Hu,Bov,Hrs,Rb Sr Prot)
115-156-003 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG (H+L)
115-156-006 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG, F(ab')₂ Fragment Specific
115-156-008 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG, Fcy Fragment Specific
115-156-020 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgM, μ Chain Specific
115-156-062 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-156-068 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-156-071 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG, Fcy Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-156-072 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG, F(ab')₂ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-156-075 AMCA-AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)
123-155-021 AMCA-AffiniPure Goat Anti-Horseradish Peroxidase
127-155-099 AMCA-AffiniPure Goat Anti-Armenian Hamster IgG (H+L) (min X Bov Sr Prot)
127-155-160 AMCA-AffiniPure Goat Anti-Armenian Hamster IgG (H+L) (min X Bov,Hu,Ms,Rb,Rat Sr Prot)
200-152-037 AMCA-IgG Fraction Monoclonal Mouse Anti-Fluorescein (FITC)
200-152-156 AMCA-IgG Fraction Monoclonal Mouse Anti-Digoxin
200-152-211 AMCA-IgG Fraction Monoclonal Mouse Anti-Biotin
205-155-108 AMCA-AffiniPure Mouse Anti-Goat IgG (H+L) (min X Ms,Hu,Rb Sr Prot)
209-155-082 AMCA-AffiniPure Mouse Anti-Human IgG (H+L) (min X Ms Sr Prot)
209-155-088 AMCA-AffiniPure Mouse Anti-Human IgG (H+L) (min X Bov,Hrs,Ms Sr Prot)
209-155-097 AMCA-AffiniPure Mouse Anti-Human IgG, F(ab')₂ Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
209-155-098 AMCA-AffiniPure Mouse Anti-Human IgG, Fcy Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
211-155-109 AMCA-AffiniPure Mouse Anti-Rabbit IgG (H+L) (min X Hu,Gt,Ms,Shp Sr Prot)
212-155-082 AMCA-AffiniPure Mouse Anti-Rat IgG (H+L) (min X Ms Sr Prot)
212-155-104 AMCA-AffiniPure Mouse Anti-Rat IgG, Fcy Fragment Specific (min X Hu,Bov,Hrs,Ms Sr Prot)
212-155-106 AMCA-AffiniPure Mouse Anti-Rat IgG, F(ab')₂ Fragment Specific (min X Hu,Bov,Hrs,Ms Sr Prot)
212-155-168 AMCA-AffiniPure Mouse Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Ms,Gt,Rb Sr Prot)
212-156-168 AMCA-AffiniPure F(ab')₂ Fragment Mouse Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Ms,Gt,Rb Sr Prot)
301-155-003 AMCA-AffiniPure Rabbit Anti-Bovine IgG (H+L)
303-155-003 AMCA-AffiniPure Rabbit Anti-Chicken IgY (IgG) (H+L)
303-155-006 AMCA-AffiniPure Rabbit Anti-Chicken IgY (IgG), F(ab')₂ Fragment Specific
303-155-008 AMCA-AffiniPure Rabbit Anti-Chicken IgY (IgG), Fc Fragment Specific
303-156-003 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Chicken IgY (IgG) (H+L)
304-155-003 AMCA-AffiniPure Rabbit Anti-Dog IgG (H+L)
304-155-008 AMCA-AffiniPure Rabbit Anti-Dog IgG, Fc Fragment Specific
305-155-003 AMCA-AffiniPure Rabbit Anti-Goat IgG (H+L)
305-155-006 AMCA-AffiniPure Rabbit Anti-Goat IgG, F(ab')₂ Fragment Specific
305-155-008 AMCA-AffiniPure Rabbit Anti-Goat IgG, Fc Fragment Specific
305-155-045 AMCA-AffiniPure Rabbit Anti-Goat IgG (H+L) (min X Hu Sr Prot)
305-155-046 AMCA-AffiniPure Rabbit Anti-Goat IgG, Fc Fragment Specific (min X Hu Sr Prot)
305-155-047 AMCA-AffiniPure Rabbit Anti-Goat IgG, F(ab')₂ Fragment Specific (min X Hu Sr Prot)
305-156-003 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Goat IgG (H+L)
305-156-006 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Goat IgG, F(ab')₂ Fragment Specific
305-156-008 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Goat IgG, Fc Fragment Specific
305-156-045 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Goat IgG (H+L) (min X Hu Sr Prot)
305-156-046 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Goat IgG, Fc Fragment Specific (min X Hu Sr Prot)
305-156-047 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Goat IgG, F(ab')₂ Fragment Specific (min X Hu Sr Prot)
307-155-003 AMCA-AffiniPure Rabbit Anti-Syrian Hamster IgG (H+L)
307-156-003 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Syrian Hamster IgG (H+L)
308-155-003 AMCA-AffiniPure Rabbit Anti-Horse IgG (H+L)
309-155-003 AMCA-AffiniPure Rabbit Anti-Human IgG (H+L)
309-155-006 AMCA-AffiniPure Rabbit Anti-Human IgG, F(ab')₂ Fragment Specific
309-155-008 AMCA-AffiniPure Rabbit Anti-Human IgG, Fcy Fragment Specific
309-155-011 AMCA-AffiniPure Rabbit Anti-Human Serum IgA, α Chain Specific
309-155-015 AMCA-AffiniPure Rabbit Anti-Human Lactoferrin
309-155-064 AMCA-AffiniPure Rabbit Anti-Human IgA+IgG+IgM (H+L)
309-155-082 AMCA-AffiniPure Rabbit Anti-Human IgG (H+L) (min X Ms Sr Prot)
309-155-095 AMCA-AffiniPure Rabbit Anti-Human IgM, Fc γ 5 μ Fragment Specific (min X Ms Sr Prot)
309-155-107 AMCA-AffiniPure Rabbit Anti-Human IgG + IgM (H+L) (min X Ms Sr Prot)
309-156-003 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Human IgG (H+L)
309-156-008 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Human IgG, Fcy Fragment Specific
309-156-043 AMCA-AffiniPure F(ab')₂ Fragment Rabbit Anti-Human IgM, Fc γ 5 μ Fragment Specific

312-155-003	AMCA-AffiniPure Rabbit Anti-Rat IgG (H+L)
312-155-020	AMCA-AffiniPure Rabbit Anti-Rat IgM, μ Chain Specific
312-155-044	AMCA-AffiniPure Rabbit Anti-Rat IgG + IgM (H+L)
312-155-045	AMCA-AffiniPure Rabbit Anti-Rat IgG (H+L) (min X Hu Sr Prot)
312-155-046	AMCA-AffiniPure Rabbit Anti-Rat IgG, Fc γ Fragment Specific (min X Hu Sr Prot)
312-155-047	AMCA-AffiniPure Rabbit Anti-Rat IgG, F(ab') ₂ Fragment Specific (min X Hu Sr Prot)
312-155-048	AMCA-AffiniPure Rabbit Anti-Rat IgG + IgM (H+L) (min X Hu Sr Prot)
312-155-049	AMCA-AffiniPure Rabbit Anti-Rat IgM, μ Chain Specific (min X Hu Sr Prot)
312-156-045	AMCA-AffiniPure F(ab') ₂ Fragment Rabbit Anti-Rat IgG (H+L) (min X Hu Sr Prot)
313-155-003	AMCA-AffiniPure Rabbit Anti-Sheep IgG (H+L)
313-155-045	AMCA-AffiniPure Rabbit Anti-Sheep IgG (H+L) (min X Hu Sr Prot)
313-155-046	AMCA-AffiniPure Rabbit Anti-Sheep IgG, Fc Fragment Specific (min X Hu Sr Prot)
313-155-047	AMCA-AffiniPure Rabbit Anti-Sheep IgG, F(ab') ₂ Fragment Specific (min X Hu Sr Prot)
313-156-003	AMCA-AffiniPure F(ab') ₂ Fragment Rabbit Anti-Sheep IgG (H+L)
315-155-003	AMCA-AffiniPure Rabbit Anti-Mouse IgG (H+L)
315-155-006	AMCA-AffiniPure Rabbit Anti-Mouse IgG, F(ab') ₂ Fragment Specific
315-155-008	AMCA-AffiniPure Rabbit Anti-Mouse IgG, Fc γ Fragment Specific
315-155-020	AMCA-AffiniPure Rabbit Anti-Mouse IgM, μ Chain Specific
315-155-044	AMCA-AffiniPure Rabbit Anti-Mouse IgG + IgM (H+L)
315-155-045	AMCA-AffiniPure Rabbit Anti-Mouse IgG (H+L) (min X Hu Sr Prot)
315-155-046	AMCA-AffiniPure Rabbit Anti-Mouse IgG, Fc γ Fragment Specific (min X Hu Sr Prot)
315-155-047	AMCA-AffiniPure Rabbit Anti-Mouse IgG, F(ab') ₂ Fragment Specific (min X Hu Sr Prot)
315-155-048	AMCA-AffiniPure Rabbit Anti-Mouse IgG + IgM (H+L) (min X Hu Sr Prot)
315-155-049	AMCA-AffiniPure Rabbit Anti-Mouse IgM, μ Chain Specific (min X Hu Sr Prot)
315-156-003	AMCA-AffiniPure F(ab') ₂ Fragment Rabbit Anti-Mouse IgG (H+L)
315-156-045	AMCA-AffiniPure F(ab') ₂ Fragment Rabbit Anti-Mouse IgG (H+L) (min X Hu Sr Prot)
315-156-046	AMCA-AffiniPure F(ab') ₂ Fragment Rabbit Anti-Mouse IgG, Fc γ Fragment Specific (min X Hu Sr Prot)
315-156-047	AMCA-AffiniPure F(ab') ₂ Fragment Rabbit Anti-Mouse IgG, F(ab') ₂ Fragment Specific (min X Hu Sr Prot)
323-155-021	AMCA-AffiniPure Rabbit Anti-Horseradish Peroxidase
415-155-166	AMCA-AffiniPure Rat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs,Rat,Rb Sr Prot)
415-156-166	AMCA-AffiniPure F(ab') ₂ Fragment Rat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs,Rat,Rb Sr Prot)
515-155-003	AMCA-AffiniPure Sheep Anti-Mouse IgG (H+L)
515-155-062	AMCA-AffiniPure Sheep Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
515-155-071	AMCA-AffiniPure Sheep Anti-Mouse IgG, Fc γ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
515-155-072	AMCA-AffiniPure Sheep Anti-Mouse IgG, F(ab') ₂ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
703-155-155	AMCA-AffiniPure Donkey Anti-Chicken IgY (IgG) (H+L) (min X Bov,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
703-156-155	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Chicken IgY (IgG) (H+L) (min X Bov,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
705-155-003	AMCA-AffiniPure Donkey Anti-Goat IgG (H+L)
705-155-147	AMCA-AffiniPure Donkey Anti-Goat IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
705-156-147	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Goat IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
706-155-148	AMCA-AffiniPure Donkey Anti-Guinea Pig IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
706-156-148	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Guinea Pig IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
709-155-073	AMCA-AffiniPure Donkey Anti-Human IgM, Fc γ Fragment Specific (min X Bov,Hrs Sr Prot)
709-155-098	AMCA-AffiniPure Donkey Anti-Human IgG, Fc γ Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
709-155-149	AMCA-AffiniPure Donkey Anti-Human IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Ms,Rb,Rat,Shp Sr Prot)
709-156-073	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Human IgM, Fc γ Fragment Specific (min X Bov,Hrs Sr Prot)
709-156-098	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Human IgG, Fc γ Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
709-156-149	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Human IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Ms,Rb,Rat,Shp Sr Prot)
711-155-152	AMCA-AffiniPure Donkey Anti-Rabbit IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rat,Shp Sr Prot)
711-156-152	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Rabbit IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rat,Shp Sr Prot)
712-155-150	AMCA-AffiniPure Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
712-155-153	AMCA-AffiniPure Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Shp Sr Prot)
712-156-150	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
712-156-153	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Shp Sr Prot)
713-155-003	AMCA-AffiniPure Donkey Anti-Sheep IgG (H+L)
713-155-147	AMCA-AffiniPure Donkey Anti-Sheep IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
713-156-147	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Sheep IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
715-155-020	AMCA-AffiniPure Donkey Anti-Mouse IgM, μ Chain Specific
715-155-140	AMCA-AffiniPure Donkey Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs,Rat Sr Prot)
715-155-150	AMCA-AffiniPure Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
715-155-151	AMCA-AffiniPure Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Rat,Shp Sr Prot)
715-156-020	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Mouse IgM, μ Chain Specific
715-156-150	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
715-156-151	AMCA-AffiniPure F(ab') ₂ Fragment Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Rat,Shp Sr Prot)
805-155-180	AMCA-AffiniPure Bovine Anti-Goat IgG (H+L) (min X Bov,Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)

Product type: Freeze-dried powder

Other means

of identification: None

1.2 Revelant identified uses of the substance or mixture identifier

For *in vitro* research use only. Not for diagnostic or therapeutic use. This is not a medical device. Contact suppliers for specific applications.

1.3 Details of the supplier of the safety data sheet

European Contact

Jackson ImmunoResearch Europe LTD
Unit 7, Acorn Business Centre
Oaks Drive, Newmarket,
Suffolk, CB8 7SY, UK
T: +44 (0) 1638 782616
F: +44 (0) 1638 668462
cuserv@jireurope.com
www.jireurope.com

Manufacturer

Jackson ImmunoResearch Laboratories, Inc.
872 West Baltimore Pike
West Grove, PA 19390
T: 800-367-5296, 610-869-4024
F: 610-869-0171
cuserv@jacksonimmuno.com
tech@jacksonimmuno.com
www.jacksonimmuno.com

E-mail address of the person responsible for this SDS: tech@jacksonimmuno.com

1.4 Emergency telephone number

Emergency Contact

Telephone number: CHEMTREC:
800-424-9300
OUTSIDE USA:
703-527-3887

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition: Mixture

Classification according to Directive 1999/45/E [DPD]

Europe

This product is not classified as dangerous after rehydration according to directive 1999/45/EC and its amendments.

Classification: Not classified.

See Section 16 for the full text of the R phrases or H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard symbol or symbols: N/A

Indication of danger: N/A

Risk phrases: After rehydration, this product is not classified according to EU legislation.

Safety phrases: Not applicable.

Hazardous ingredients: The only danger of this product is associated with sodium azide which is present in a very small amount. After rehydration, sodium azide is below the threshold level of 1% for a toxic chemical.

Supplemental label elements: Not applicable.

Special packaging requirements

Containers to be fitted with child-resistant fastenings: Not applicable.

Tactile warning of danger: Not applicable.

2.3 Other hazards

Other hazards which do not result in classification: N/A

SECTION 3: Composition/information on ingredients

Substance/mixture: Mixture

Chemical Name	CAS#	EC #	% (w/w)
Sodium Azide	26628-22-8	247-852-1	2 [0.05% (w/v) after rehydration]
Sodium Phosphate	7558-79-4	231-448-7	4
AMCA -conjugated antibody or -streptavidin	N/A	N/A	5
Sodium Chloride	7647-14-5	231-598-3	44
Bovine Serum Albumin	N/A	N/A	45

The mixture is not considered to be hazardous after rehydration for use.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact: If this product enters the eyes, flush the eyes with gently running water for at least 15 minutes. If inflammation occurs, get medical attention.

Inhalation: Vapors of these products are likely to be only water vapors, so no adverse health effects are expected if vapors are inhaled. If irritation occurs, get medical attention.

Skin contact: Basic hygiene should prevent any problems. If contact with these products leads to reddening, inflammation, or irritation, flush exposed area with running water and get medical attention.

Ingestion: Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. Give small quantities of water to drink. Do not induce vomiting unless directed by medical personnel. These products are for *in vitro* research use only, not for household, diagnostic, or therapeutic use. They are not medical devices. If these products are accidentally swallowed, no adverse health effects are expected. However, no special precautions are taken to remove or detect the possible presence of endotoxin or pyrogens. If fever or adverse effects are experienced, get medical attention.

Protection of first-aiders: No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects

Eye contact: No known significant effects or critical hazards.

Inhalation: No known significant effects or critical hazards.

Skin contact: No known significant effects or critical hazards.

Ingestion: No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact: No specific data.

Inhalation: No specific data.

Skin Contact: No specific data.

Ingestion: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments: No specific treatment.

SECTION 5: Fire-fighting measures

5.1

Extinguishing media

Suitable extinguishing media: Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture: In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous combustion products: Decomposition products may include oxides of carbon, nitrogen, and phosphorus in very small quantities.

5.3 Advice for fire fighters

Special precautions for fire fighters: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire fighters: Fire fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire fighters (including helmets, protective boots, and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6. Accidental release measures

6.1 Personal

precautions, protective equipment, and emergency procedures

For non-emergency personnel: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas.

Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

For emergency responders:

6.2 Environmental precautions: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil, or air).

6.3 Methods and materials for containment and cleaning up

Small spill: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water soluble. Alternatively, or if water insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill: Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements, or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material, e.g. sand, earth, vermiculite, or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via licensed waste disposal contractor.

6.4 Reference to other sections: See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information

in this section contains generic advice and guidelines. The list of Identified Uses in Section 1 should be consulted for any available use specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures: Put on appropriate protective equipment (see Section 8).

Advice on general occupational hygiene: Eating, drinking, and smoking should be prohibited in areas where material is handled, stored, and processed. Workers should wash hands and face before eating, drinking, and smoking. Remove contaminated clothing and protective equipment entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities: Store at 2-8 ° C under sterile conditions. Store in original container away from incompatible materials (see Section 10) and food and drink. Keep container tightly sealed until ready to use. Prepare working dilution fresh each day. Remove aliquots for dilution and reseal container under sterile conditions. Do not store in unlabeled container. Use appropriate containment to avoid environmental contamination. Consult Product Specification sheets for additional storage information.

7.3 Specific end uses

Recommendations: Not available.

Industrial sector specific solutions: Not available.

SECTION 8: Exposure controls/personal protection

The information

in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

8.1 Control parameters

Occupational exposure limits

Europe: No exposure limit value known.

Recommended monitoring procedures: If this product contains ingredients with exposure limits, personal, workplace atmosphere, or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to European Standard EN689 for methods for the assessment of exposure by inhalation to chemical agents and national guidance documents for methods for the determination of hazardous substances.

Derived effect levels

No DELs available

Predicted effect concentrations

No PECs available

8.2 Exposure controls

Appropriate engineering controls: No special ventilation requirements. Good general ventilation should be sufficient to control worker exposure to airborne contaminants. If this product contains ingredients with exposure limits, use process enclosures, local exhaust ventilation, or other engineering controls to keep worker exposure below any recommended or statutory limits.

Individual protection measures

Hygiene measures: Wash hands, forearms, and face thoroughly after handling chemical products, before eating, smoking, and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure

the eyewash station and safety showers are close to the workstation location.

Eye/face protection: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, or dusts.

Skin protection

Hand protection: Chemical resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection: Use a properly-fitted, air-purifying, or air-fed respirator complying with an approved standard if a risk assessment indicates this is a necessity. Respirator selection must be on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.

Environmental exposure controls: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters, or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information

on basic physical and chemical properties

Appearance

Physical state: Liquid

Color: Colorless, as water

Odor: Odorless, as water

Odor threshold: Not available

pH: 7.6

Melting point/freezing point: Not available

Initial boiling point and boiling range: Not available

Flash point: Not available

Evaporation rate: Not available

Flammability: Not available

Burning time: Not available

Burning rate: Not available

Upper/lower flammability or explosive limits: Not available

Vapor pressure: Not available

Vapor density: Not available

Relative density: Not available

Solubility(ies): Soluble in warm and cold water

Partition coefficient: n-octanol/water

Auto-ignition temperature: Not available

Decomposition temperature: Not available

Viscosity: Not available

Explosive properties: Not available

Oxidizing properties: Not available

9.2 Other information

No additional information

SECTION 10: Stability and reactivity

10.1 Reactivity:

No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability: The product is stable.

10.3 Possibility of hazardous reactions: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid: No specific data.

10.5 Incompatible materials: No specific data.

10.6 Hazardous decomposition products: Under normal conditions of storage and use, hazardous decomposition products will not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Sodium Chloride: Oral Rat, LD50, 3,000 mg/kg

Sodium Phosphate: Oral Rat, LD50, 17g/kg

Sodium Azide: Oral Rat, LD50, 27 mg/kg

Antibody/Serum Protein: Not established

Irritation/Corrosion

Conclusion/Summary: Not available.

Sensitizer

Conclusion/Summary: Not available.

Mutagenicity

Conclusion/Summary: Not available

Carcinogenicity

Conclusion/Summary: Not available

Reproductive toxicity

Conclusion/Summary: Not available

Teratogenicity

Conclusion/Summary: Not available

Information on the likely routes of exposure: Routes of entry anticipated: Oral, Dermal, and Inhalation

Potential acute health effects

Inhalation: No known significant effects or critical hazards.

Ingestion: No known significant effects or critical hazards.

Skin contact: No known significant effects or critical hazards.

Eye contact: No known significant effects or critical hazards.

Symptoms related to the physical, chemical, and toxicological characteristics

Inhalation: No specific data
Ingestion: No specific data
Skin contact: No specific data
Eye contact: No specific data

Delayed, immediate, and chronic effects from short and long term exposure

Short term exposure

Potential immediate effects: Not available
Potential delayed effects: Not available

Long term effects

Potential immediate effects: Not available
Potential delayed effects: Not available

Potential chronic health effects

Conclusion/Summary: Not available
General: No known significant effects or critical hazards.
Carcinogenicity: No known significant effects or critical hazards.
Mutagenicity: No known significant effects or critical hazards.
Teratogenicity: No known significant effects or critical hazards.
Developmental effects: No known significant effects or critical hazards.
Fertility effects: No known significant effects or critical hazards.

Other information: Not available

SECTION 12: Ecological information

12.1 Toxicity

Conclusion/Summary: Not available

12.2 Persistence and degradability

Conclusion/Summary: Not available

12.3 Bioaccumulative potential. Not available

12.4 Mobility in soil

Soil/water partition coefficient: Not available
Mobility: Not available

12.5 Results of PBT and vPvB assessment

PBT: Not applicable
vPvB: Not applicable

12.6 Other adverse effects: No known significant effects or critical hazards.

SECTION 13. Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

Product

Methods of disposal: The generation of waste should be avoided or minimized wherever possible. Significant quantities of waste product residues should not be disposed of via the foul sewer but processed in a suitable effluent treatment plant. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Disposal of this product, solutions, and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers.

Hazardous waste: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 91/689/EEC.

Packaging

Methods of disposal: The generation of waste should be avoided or minimized whenever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers.

SECTION 14: Transport information

	ADR/RID	ADN/ADNR	IMDG	IATA
14.1 UN number	Not available	Not available	Not available	Not available
14.2 UN proper shipping name	Not available	Not available	-	-
14.3 Transport hazard class(es)	Not available	Not available	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No	No	No	No
14.6 Special precaution for user	Not available	Not available	Not available	Not available
Additional information	-	-	-	-

14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the and the IBC Code: Not available.

SECTION 15: Regulatory information

15.1 Safety, health, and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorization

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market, and use of certain dangerous substances, mixtures, and articles: Not applicable.

Other EU regulations

Europe inventory: Not determined.

Black List Chemicals: Not listed.

Priority List Chemicals: Not listed.

Integrated pollution prevention and control list (IPPC) - Air: Not listed.

IPPC - Water: Not listed.

National Regulations

15.2 Chemical Safety Assessment: This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information

Abbreviations and acronyms: ATE = Acute Toxicity Estimate

CLP = Classification, Labelling, and Packaging Regulation [Regulation (EC) No. 1272/2008]

DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard Statement

PNEC = Predicted No Effect Concentration

RRN = REACH Registration Number

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
-----------------------	----------------------

Europe

Full text of abbreviation H statements: Not applicable.

Full text of classifications [CLP/GHS]: Not applicable.

Full text of abbreviated R phrases: Not applicable.

Full text of classifications[DSD/DPD]: Not applicable.

Date of printing: 9-13-12

Date of issue/Date of revision: 9-13-12

Date of previous issue: No previous validation.

Version: 1.0

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.